Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010

Although pancreatic cancer is recognized as a major risk factor for venous thromboembolism, the exact magnitude of the problem is not known. The incidence varies from 17% to 57% depending on different studies. The effect of venous thromboembolism on outcomes in not well defined and there is no known...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the Pancreas 2010-07, Vol.11 (4), p.331-333
Hauptverfasser:	Shah, Manasi M, Saif, Mumhammad Wasif
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - complications Adenocarcinoma - therapy Antineoplastic Combined Chemotherapy Protocols - administration & dosage Fibrinolytic Agents - administration & dosage Heparin, Low-Molecular-Weight - administration & dosage Humans Pancreatic Neoplasms - complications Pancreatic Neoplasms - therapy Polypharmacy Risk Factors Thrombosis - complications Thrombosis - etiology Thrombosis - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Although pancreatic cancer is recognized as a major risk factor for venous thromboembolism, the exact magnitude of the problem is not known. The incidence varies from 17% to 57% depending on different studies. The effect of venous thromboembolism on outcomes in not well defined and there is no known independent predictor of survival. This review is an update from the current American Society of Clinical Oncology (ASCO) Annual Meeting regarding the impact of thrombotic events on the clinical outcomes, the association of tissue factor and thrombotic events, and the primary prevention of venous thromboembolism in pancreatic cancer patients undergoing active treatment.
ISSN:	1590-8577